This company listing is no longer active
Epizyme Dividende
Zukünftiges Wachstum Kriterienprüfungen 0/6
Wichtige Informationen
n/a
Dividendenausschüttung
n/a
Ausschüttungsquote
Durchschnittlicher Branchenertrag | 2.8% |
Nächster Dividendenzahlungstermin | n/a |
Ex-Dividendendatum | n/a |
Dividende pro Aktie | n/a |
Gewinn pro Aktie | -US$1.23 |
Erwartete Dividendenrendite in 3 Jahren | 0% |
Aktuelle Dividendenentwicklung
Keine Aktualisierungen
Recent updates
Epizyme GAAP EPS of -$0.21, revenue of $27.5M
Aug 09Epizyme Acquisition By Ipsen: CVR Value
Jul 05Some Epizyme, Inc. (NASDAQ:EPZM) Analysts Just Made A Major Cut To Next Year's Estimates
May 16Epizyme: Taking Advantage Of Recent Sell-Off
Nov 25Health Check: How Prudently Does Epizyme (NASDAQ:EPZM) Use Debt?
Sep 14Industry Analysts Just Made A Sizeable Upgrade To Their Epizyme, Inc. (NASDAQ:EPZM) Revenue Forecasts
Aug 10Epizyme: Potential Comeback With Tazemetostat After Initial Sales Challenge
Jun 22Is Epizyme (NASDAQ:EPZM) Using Too Much Debt?
Jun 08Epizyme gains as peer Constellation attracts sizable premium from MorphoSys
Jun 02Epizyme, Inc. 2021 Q1 - Results - Earnings Call Presentation
May 07Epizyme, Inc. (NASDAQ:EPZM) Analysts Just Trimmed Their Revenue Forecasts By 41%
Feb 25Is Epizyme (NASDAQ:EPZM) Using Too Much Debt?
Jan 16Epizyme says Boehringer terminates collaboration agreement
Dec 24Would Shareholders Who Purchased Epizyme's (NASDAQ:EPZM) Stock Year Be Happy With The Share price Today?
Dec 12Epizyme Q3 2020 Earnings Preview
Nov 05Stabilität und Wachstum des Zahlungsverkehrs
Rufe Dividendendaten ab
Stabile Dividende: Insufficient data to determine if EPZM's dividends per share have been stable in the past.
Wachsende Dividende: Insufficient data to determine if EPZM's dividend payments have been increasing.
Dividendenrendite im Vergleich zum Markt
Epizyme Dividendenrendite im Vergleich zum Markt |
---|
Segment | Dividendenrendite |
---|---|
Unternehmen (EPZM) | n/a |
Untere 25 % des Marktes (US) | 1.6% |
Markt Top 25 % (US) | 4.8% |
Branchendurchschnitt (Biotechs) | 2.8% |
Analystenprognose in 3 Jahren (EPZM) | 0% |
Bemerkenswerte Dividende: Unable to evaluate EPZM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
Hohe Dividende: Unable to evaluate EPZM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Gewinnausschüttung an die Aktionäre
Abdeckung der Erträge: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Barausschüttung an die Aktionäre
Cashflow-Deckung: Unable to calculate sustainability of dividends as EPZM has not reported any payouts.